Drug Trial Radar · NCT04084678
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
Jan 20, 2021
Primary completion
Apr 12, 2023
Study completion Apr 12, 2023
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment.
Conditions
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
Interventions
RalinepagDrug
Oral ralinepag
PlaceboDrug
Matching oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Peak VO2 Assessed by CPETTime frame: Baseline to Week 28
Locations
33 sites in 12 countries. Site status is shown where the registry gives one.
Banner University Medical Center (University of Arizona)
Tucson, Arizona
University of Colorado Anschutz Medical Campus
Aurora, Colorado
National Jewish Health
Denver, Colorado
Tampa General Hospital/University of South Florida Center for Advanced Lung Disease and Lung Transplant
Tampa, Florida
Medical College of Wisconsin/Froedtert Hospital
Milwaukee, Wisconsin
Hospital Britanico de Buenos Aires
Ciudad Autónoma de Bs. As., Argentina
Instituto de Cardiología de Corrientes
Corrientes, Argentina
Macquarie University
North Ryde, New South Wales, Australia
Westmead Hospital, Dept Respiratory and Sleep Medicine
Westmead, New South Wales, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Ordensklinikum Linz GmbH, Elisabethinen
Linz, Austria
AKH Wien, Innere Med. II, Kardiologie
Vienna, Austria
Erasme University Hospital - Department of Cardiology
Brussels, Belgium
Gasthuisberg University Hospital - Department of Pulmonology
Leuven, Belgium
Centro de Hipertensão Pulmonar
Porto Alegre, Brazil
Hospital Madre Teresa
Belo Horizonte, Minas Gerais, Brazil
Hospital Sao Paulo
São Paulo, São Paulo, Brazil
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo - InCor-HCFMUSP
São Paulo, São Paulo, Brazil
Peter Lougheed Center
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
London Health Science Centre- Victoria Hospital
London, Ontario, Canada
Thoraxklinik-Heidelberg, Zentrum für Pulmonale Hypertonie
Heidelberg, Baden-Wurttemberg, Germany
Universitätsklinikum Carl Gustav Carus TU Dresden, Medizinische Klinik I, Abteilung für Pneumologie
Dresden, Saxony, Germany
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
Centro Cardiologico Monzino, IRCCS
Milan, Italy
AOU Policlinico Umberto I
Rome, Italy
Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Kardiologii z Oddziałem Intensywnego Nadzoru Kardiologicznego
Bialystok, Poland
Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Oddział Kardiologiczny
Otwock, Poland
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clínic I Provincial de Barcelona
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Imperial college Healthcare NHS Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.